Loading
A phase 2 trial of Artesunate ointment in vulvar cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) is a phase 2 interventional study registered as NCT06075264 by Frantz Viral Therapeutics, LLC, with 27 participants planned, started 2023-12-06 and due to reach its primary completion in 2026-12. Interventions recorded: Artesunate ointment and Placebo ointment.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Frantz Viral Therapeutics and the tag pipeline.
Shares Vulvar cancer and the tag pipeline.
Shares Vulvar cancer and the tag pipeline.
Shares Vulvar cancer and the tag pipeline.
Shares HPV-associated vulvar squamous cell carcinoma, Vulvar cancer.
Shares HPV-associated vulvar squamous cell carcinoma, Vulvar cancer.
Shares HPV-associated vulvar squamous cell carcinoma, Vulvar cancer.
Shares HPV-associated vulvar squamous cell carcinoma, Vulvar cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/